Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.11, 2011-11, pp. : 977-988

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Agents for the Treatment of Advanced Renal Cell Carcinoma

Current Drug Targets, Vol. 6, Iss. 7, 2005-11 ,pp. : 835-846

Bentham Science Publishers

Access to resources Recommend Favorite

Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

Current Clinical Pharmacology, Vol. 6, Iss. 3, 2011-08 ,pp. : 181-188

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapies in the Treatment of Renal Cell Carcinoma

Current Medicinal Chemistry, Vol. 15, Iss. 12, 2008-05 ,pp. : 1166-1174

Bentham Science Publishers

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma

By Escudier Bernard Albiges Laurence

Drugs, Vol. 71, Iss. 9, 2011-06 ,pp. : 1179-1191

Adis International

Access to resources Recommend Favorite

Quantifying Women's Stated Benefit–Risk Trade-Off Preferences for IBS Treatment Outcomes

By Johnson F. Reed Hauber A. Brett Özdemir Semra Lynd Larry

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 418-423

Blackwell Publishing

Access to resources Recommend Favorite